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Key
Messages
>   Farmers have a strong preference for a porcine cysticercosis vaccination
    that would be accompanied by premium prices when selling their pigs
>   The current market is unlikely to meet these premiums without subsidies
>   Farmers would prefer a vaccine with viability detector (showing the vaccine
    is effective), probably because there is generally high concern over low 
    quality products 
>   Farmers prefer a single dose product (the current formulation requires 
    at least two doses) 
>   For traders, the most important pig characteristic is weight, although they 
    also reported being concerned about consumer health
>   Consumers’ preferences are primarily driven by characteristics that can 
    be directly experienced, such as taste and price rather than by concerns 
    over food safety.  
>   Entry of the accompanying de-wormer oxfendazole (Paranthic 10%™)
    in the market should be accompanied by creating awareness on its unique 
    effectiveness against porcine cysticercosis as other de-wormers are more 
    competitive on price
>   A constraint for distributors is that the vaccine and de-wormers are not 
    packaged together 
>   The ‘added value’ of the porcine cysticercosis vaccine will accrue more 
    to the public health sector than the farmer. However, deworming could 
    potentially give economic benefits to farmers through improved pig weight
>   Farmers’ lack of awareness about the benefits of vaccination in general
    (especially for pigs) is one of the biggest barriers to product entry into




Pig health is a critical issue in modern Uganda. Not
only does the country have the largest pig population
in East Africa, it also has the most rapidly growing
pig population in sub-Saharan Africa and the highest
per capita pork consumption in Eastern Africa
(FAOSTAT, 2010). Porcine cysticercosis (PC) is a 
disease of pigs caused by larval cysts of the human
T. solium tapeworm. Pigs are infected when they eat
tapeworm eggs shed in the faeces of a human 
tapeworm carrier. Humans are infected when they
eat tissues from pigs that contain larvae (cysticerci).
These larvae establish as tapeworms in the human
gut and shed eggs in human faeces. However, if 
humans ingest tapeworm eggs in contaminated
food or water, these can establish as cysts in the
brain, eye or other tissues and these can have 
serious consequences such as epilepsy. 
New tools have become available for the control 
of PC that could help to break the disease cycle,
namely a recombinant vaccine antigen, TSOL18
(Cysvax™), combined with benzimidazole drug
oxfendazole (Paranthic 10%™), a pig de-wormer.
More recently, TSOL18 has been proven to be highly
effective against naturally acquired infection with 
T. solium in pigs. Application of TSOL18 together
with a single treatment of pigs with oxfendazole
achieved the complete elimination of transmission 
of the parasite by pigs (Lightowlers, 2010). 
These drugs, although licensed elsewhere, are not
currently on the market in Uganda. GALVmed, a
product development and adoption partnership
focusing on livestock health, has carried out field 
trials in Uganda to control pig tapeworm through the
combined use of vaccine and wormer. Results from
the trials have confirmed efficacy. A market scoping
study has also been conducted to assess the 
potential of marketing Cysvax™ and Paranthic
10%™as private goods.
Picture 1: Confined sow in Hoima district, Uganda (Michel Dione/ILRI)
Picture 2: Bottle of TSOL 18 vaccine (Indian Immunologicals Limited)
Picture 3: Pork infested with cysts (Michel Dione/ILRI)
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It is difficult to estimate demand for products that are not yet marketed. For this reason, we conducted a
range of studies in different sites with different actors. Eight separate market scoping studies took place in
Uganda’s Masaka, Kampala and Bukedea districts (Figure 2). Masaka was selected because it has the
highest pig population density in Uganda, Bukedea was selected because it is a site for the GALVmed PC
vaccine field trials and Kampala was selected because it has highest number of pork consumers in the
country. The studies targeted at different nodes of the pig value chain:
>    Farmers’ willingness to pay for TSOL18 vaccine and oxfendazole
>    Traders’ willingness to pay for porcine cysticercosis-vaccinated pigs
>    Consumer perceptions on porcine cysticercosis-free pork
>    Consumers’ preference for safe food from animal source
>    Therapeutic product profiling
>    Service providers’ willingness to sell the TSOL18 vaccine and oxfendazole
>    Potential for large drug distributors to market TSOL18 and oxfendazole
>    Stakeholder consultation
Figure 2:
Map of Uganda showing the study sites
Different studies undertaken
Page 6
Characteristics of TSOL18 and oxfendazole
TSOL18 vaccine (Cysvax™): Containing the T. solium oncosphere antigen (TSOL18),
150 ug/ml adjuvanted with mineral oil. 
>    Dose of 1 ml per pig administered by intramuscular injection (deep intramuscular injection
      behind ear).
Oxfendazole (Paranthic 10%™): Containing 10% w/v oxfendazole, oral suspension. 
Dosage of 3 ml/10kg body weight (30 mg/kg) administered orally (by drenching) concurrently
with the vaccine primary and booster vaccinations, as well as re-vaccination to treat
infected pigs.
>    The TSOL18 vaccine is effective when both primary and booster vaccines are applied.
>    Primary vaccination is given to pigs at least 2 months old.
>    Booster vaccine can be given from three weeks after the primary vaccine. 
>    Immunity in pigs develops within two weeks of the booster dose. 
>    Re-vaccination is needed six months later if the pig is still on the farm (not yet sold).
>    The vaccine is not thermostable and needs to be stored and transported at temperatures 
      between 2○C and 8○C (thus requiring a cold chain).
>    The withdrawal period for the vaccine is zero days, but oxfendazole requires a withholding 
      period of 21 days.
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Results
The market scoping exercise was informative. Key findings include: 
Farmers indicated a willingness to pay US$0.4 more for every additional dollar in price 
per pig (approximately of 40kg liveweight). This suggests that without a premium price
for vaccinated pigs, uptake by farmers may not succeed. The choice experiment showed
few of farmers (only 19%) selected the option of the vaccine with its current combination
of attributes and were only willing to pay US$2.6 per pig (including administration costs).
They were willing to pay US$1.7 more for a vaccine administered once versus three
times. Many farmers (38 – 50%) selected choices options that had combinations 
of improved attributes of the vaccine and a higher price premium of vaccinated pigs.
They were willing to pay between US$12.0 and US$17.0 for this combination (which
does not currently exist). 
Awareness about PC was high among pig traders who said they refuse to purchase pigs
suffering from PC. Other studies, however, show that pigs affected with PC are bought 
by traders. Results show that the traders’ most preferred attribute for pigs was liveweight,
although they also reported concerns about consumer health. Weight gain can be enhanced
through appropriate deworming regimes such as through the use of oxfendazole, 
although genetics and diet are probably more important determinants of weight.
Consumer focus groups considered hygiene as the most important way of ensuring that
pork is safe for consumption. They also noted willingness to pay more for pork certified to
be PC-free as long as their safety is guaranteed. However, in a real-life proxy experiment
using eggs rather than pork, when consumers had the option to buy eggs with different
attributes, purchases were not driven by food safety. Although consumers may be aware
of safe foods, they prefer products with taste, price, and accessibility benefits over those
certified for food safety. 
There appears to be substantial demand for livestock de-wormers in Uganda, and the
market for de-wormers is relatively crowded. Animal health service providers preferred
ivermectin, while farmers preferred levamisole and albendazole. Albendazole and Erafen 5
(active ingredient fenbendazole) are potential competitors for oxfendazole (note that 
neither have good efficacy against PC). It will be hard for oxfendazole to penetrate and
capture market shares for pig deworming given that most other drugs are cheaper per
dose than Paranthic 10%™ (active ingredient oxfendazole), an important consideration
for farmers. Some are also more effective at managing other parasites which farmers are
concerned about (e.g. ivermectin is effective against mange). Even though oxfendazole
is comparatively expensive, there is an opportunity for it to capture some market share 
because it is a broad-spectrum de-wormer as well as being effective against PC. 
For the TSOL18 vaccine-oxfendazole combination to be competitive (viewed simply 
as a de-wormer), it should be priced between US$1.6 and US$6.0, per the drug stockist
scoping study. However, the fact that the vaccine and de-wormer are not packaged
together makes the combination unattractive to distributors because of anticipated 
challenges in acquiring both products at the same time when needed. 
Farmers 
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About 1.1 million households’ rear pigs in Uganda (UBOS and MAAIF, 2009).
The survey also indicated that 68% of pig farmers deworm at least twice
per year. The farmers that deworm are more likely to take up the vaccine
since they can afford deworming, which would mean that these 748,000
households would be suitable for targeting. Districts with high PC prevalence
would have higher penetration rates than those with low prevalence rates.
Assuming a penetration rate of 1%, approximately 74,800 households
would vaccinate their pigs. The highest market potential would be in Eastern
Uganda (ex. Kumi, Iganga, Soroti, Kamuli, Mbale, Pallisa), with high the PC
prevalence rates, which makes the prospect of vaccination attractive,
although lower pig populations compared to the other regions such as 
those in central (ex. Masaka, Mukono, Wakiso, Luwero, Mpigi). 
Some distributors in Uganda have exclusive agreements to distribute 
specific products from manufacturers. This type of agreement would be 
difficult to use in terms of the TSOL18 vaccine-oxfendazole combination,
and some of these distributors have well-established sales routes and 
market share. The National Drug Authority has strict guidelines for registering
vaccines that can sometimes be cumbersome. Additionally, farmers’ poor
attitude and lack of awareness about vaccination (especially pigs) is one of
the biggest barriers. This can be illustrated by the case of free rabies 
vaccines that are also not readily taken up by farmers. Farmers are more
used to deworming their pigs, and it is a cheaper option compared to the
TSOL18 vaccine, meaning farmers might not use the vaccine since its price
is high compared to conventional dewormers.
The ‘added value’ of the PC vaccine seems to be public health benefits
rather than economic benefits, with the deworming component providing
some economic benefits. Thus, the vaccine needs to be sold as a product
solving a public health need. This would mean that there is a need to
demonstrate PC correlation with cases of epilepsy in humans in Uganda to
persuade policymakers. In the meantime, since deworming is an acceptable
and routine animal husbandry practice, the value proposition could focus 
on reducing deworming times (though the vaccine only fights one type of
worm). Another idea is to combine the vaccine with other vaccines for pig
diseases of higher concern to farmers (such as African swine fever); for this,
it would be imperative to rely on the private sector since the bulk of 














The efficacy of the TSOL18 vaccine has been demonstrated in technical studies. It has also been
demonstrated that oxfendazole is effective against the cysts stage of the disease. However, in its 
current form, the TSOL18 vaccine-oxfendazole combination is not likely to achieve desirable market
penetration as a private good. Substantial adoption of PC vaccine will require an integrated approach
that will put the farmer at the center while considering other value chain actors. Long term education
of value chain actors about the public importance of the disease, backed up with economic incentives
such as marketing opportunities for quality animals can substantially improve adoption. Furthermore,
a ‘One Heath’ approach – Public Private Partnership forum for stakeholder engagement is necessary
with the Government supporting intervention measures.
Recommendations
Product manufacturer: Further development of the vaccine is needed to make it more 
cost-effective and reduce the number of injections required to achieve immunity. A smaller
packing size of oxfendazole (ex.10 ml) would also be preferred. Other areas for development
are inclusion of a viability marker and development of a thermos-stable vaccine.
Drug distributors: They should be supported (e.g. subsidized) by the Government to import
the product, if this approach can be shown to be effective and cost-effective. Government
should work hand-in-hand with the distributor to make the product accessible to farmers.
There is also need to proactively build farmer’s trust in drug distribution system and vaccine
use. Market entry of oxfendazole should be accompanied by advertisement to show why
oxfendazole is superior to the potential competing products.
Animal health service providers: They are the major source of information for farmers and
should be involved in awareness campaigns about PC. They should also be trained in disease
recognition and management of affected pig carcasses.
Farmers: The product packaging and cost of the TSOL18 vaccine and oxfendazole 
combination should be reduced so that farmers have easy access to it. Farmers should be
sensitized about the effects of the disease on pigs and its public health importance. 
Traders/butchers: this category of actors can be change agents, because they are highly
connected to pig farmers and know all trading networks. They also have high awareness
about the disease. They should be trained on the effects of the disease in humans and policy




Consumers: There is need for consumer sensitisation campaigns to enhance appreciation 
of safe food.
Government: A major role should be played by the Government. This includes: (a) engagement
and support to promote the TSOL18 vaccine-oxfendazole combination, as well as to lead 
disease eradication by facilitating market regulation to enable product entry and market growth
and enabling the distribution environment by enforcing regulation on disease control; (b) support
mass sensitisation about the control of PC amongst stakeholders at all levels. 
Researchers: there is a need to carry out socioeconomic impacts studies of the disease to
generate evidence for decision-makers to justify funding. Studies on the productivity losses 
associated with pig parasites and the cost-benefit of different de-wormers would help identify
the most suitable de-wormers under different circumstances and the appropriate private-public
cost sharing. There is also need to generate evidence on the different options for managing 
PC and there comparative cost, benefit, and feasibility.
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